ORAMED PHARMACEUTICALS INC. Federal Income Tax Expense (Benefit), Continuing Operations
ORAMED PHARMACEUTICALS INC. (ORMP) reported Federal Income Tax Expense (Benefit), Continuing Operations of $3.18 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations · last filed 2025-03-27
- ORAMED PHARMACEUTICALS INC. federal income tax expense (benefit), continuing operations for fiscal 2024 was $3.18M.
- ORAMED PHARMACEUTICALS INC. federal income tax expense (benefit), continuing operations for fiscal 2016 was -$15.00K.
- ORAMED PHARMACEUTICALS INC. federal income tax expense (benefit), continuing operations for fiscal 2013 was -$13.00K.
- ORAMED PHARMACEUTICALS INC. federal income tax expense (benefit), continuing operations for fiscal 2012 was -$8.00K.
| Period end | Federal Income Tax Expense (Benefit), Continuing Operations 12 month | Federal Income Tax Expense (Benefit), Continuing Operations 12 month as first filed | Federal Income Tax Expense (Benefit), Continuing Operations 125 month | Federal Income Tax Expense (Benefit), Continuing Operations 137 month |
|---|---|---|---|---|
| 2024-12-31 | $3.18M 10-K · filed 2025-03-27 | |||
| 2016-08-31 | -$15.00K 10-K · filed 2018-11-28 | |||
| 2013-08-31 | -$13.00K 10-K · filed 2015-11-25 | -$12.96K 10-K · filed 2013-11-27 | $67.39K 10-K · filed 2013-11-27 | |
| 2012-08-31 | -$8.00K 10-K · filed 2014-11-14 | -$7.57K 10-K · filed 2012-12-12 | $62.00K 10-K · filed 2012-12-12 | |
| 2011-08-31 | -$33.57K 10-K · filed 2012-12-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |